Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lofexidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 16/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 16/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 16/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 6/20 | 0.61 |
| ▸ | MAOB | P27338 | 6/20 | 0.61 |
| ▸ | NISCH | Q9Y2I1 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levlofexidine SCHEMBL947241 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Dexlofexidine SCHEMBL124602 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL678553 | 0.98 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL22616208 | 0.98 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL3500726 | 0.98 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL124601 | 0.98 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL22616113 | 0.92 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL22616152 | 0.92 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL22616174 | 0.92 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL22616269 | 0.91 | ADRA2A (0.82) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4326 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| US-12472158-B2 | Methods of treating trigeminal nerve pain | VANDERBILT UNIVERSITY (US) | 2025-11-18 | — | — | US | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250246289-A1 | DYNAMICALLY TARGETING SUBSTANCE USE DISORDERS AND CONDITIONS VIA PERSONALIZED DIGITAL THERAPEUTICS | Click Therapeutics, Inc. (US) | 2025-07-31 | — | — | US | claimed |
| US-12351558-B2 | Process for the synthesis of lofexidine | MEDICHEM, S.A. (ES) | 2025-07-08 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | claimed |
| EP-0081748-B1 | PROCESS FOR THE PREPARATION OF (-)-2-(1-(2,6-DICHLOROPHENOXY)-ETHYL)-1,3-DIAZACYCLOPENT-2-ENE | A. Nattermann & Cie. GmbH (DE) | 1987-02-25 | — | — | EP | claimed |
| EP-0082364-B1 | (+)-2-(1-(2,6-DICHLOROPHENOXY)-ETHYL)-1,3-DIAZACYCLOPENT-2-ENE, PROCESS FOR ITS PREPARATION AND ITS USE IN PHARMACEUTICAL COMPOSITIONS | A. Nattermann & Cie. GmbH (DE) | 1986-04-23 | — | — | EP | claimed |
| US-4575510-A | LOFEXIDINE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-03-11 | — | — | US | claimed |
| EP-0170193-A2 | Feedstuff additive for the growth promoting of agricultural useful animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-02-05 | — | — | EP | claimed |
| US-4518783-A | Process for producing (-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene | A. NATTERMANN & CIE GMBH (DE) | 1985-05-21 | — | — | US | claimed |
| US-4443464-A | (+)-2-[1-(2,6-Dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene and the method for the treatment of human beings suffering from nervous disarrangements, in particular migraine | A. NATTERMANN & CIE GMBH (DE) | 1984-04-17 | — | — | US | claimed |
| EP-0081748-A2 | Process for the preparation of (-)-2-(1-(2,6-dichlorophenoxy)-ethyl)-1,3-diazacyclopent-2-ene | A. Nattermann & Cie. GmbH (DE) | 1983-06-22 | — | — | EP | claimed |
| US-4382946-A | Method of alleviating withdrawal symptoms | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-05-10 | — | — | US | claimed |
| US-4312879-A | Clonidine and lofexidine as antidiarrheal agents | RICHARDSON-MERRELL INC. (US) | 1982-01-26 | — | — | US | claimed |
| US-4189492-A | SYNERGISTIC | RICHARDSON-MERRELL INC. (US) | 1980-02-19 | — | — | US | claimed |